HOTH - 5 Top Weekly NASDAQ Biotech and Pharma Stocks: Genocea Biosciences on Top
The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) was in the red last week, dropping from 3,279.52 points on Tuesday (May 28) to 3,167.47 points as of 1:36 p.m. EDT on Friday (May 31).
Despite the index’s dip, a number of NASDAQ biotech and pharma stocks still had notable share price increases last week. In particular, Genocea Biosciences (NASDAQ:GNCA) spiked on its announcement that the Journal of Clinical Oncology chose the company’s GEN-009 clinical results to be presented at the 2019 ASCO Meeting, which took place on June 1.
Other top gainers last week are as follows:
- Genocea Biosciences
- Outlook Therapeutics (NASDAQ:OTLK)
- Hoth Therapeutics (NASAQ:HOTH)
- Aveo Oncology (NASDAQ:AVEO)
- Evofem Biosciences (NASDAQ:EVFM)
Here’s a closer look at those companies and what may have moved their share prices over the week.
Genocea Biosciences
Genocea Biosciences is focused on developing personalized cancer immunotherapies. Its ATLAS technology platform helps the company target immunotherapies based on an individual’s tumor antigen-specific T cell responses.
As such, the company is advancing programs based off ATLAS, including its GEN-009 neoantigen vaccine candidate, which is in a Phase 1/2a clinical trial in a various solid tumors. The company’s other candidate, GEN-011, is a neoantigen-specific adoptive T cell therapy for which the company anticipates filing an Investigational New Drug application sometime in the first half of 2020.
Shares of Genocea Biosciences increased 34.47 percent last week to reach US$5.73 as of 2:19 p.m. EDT on Friday.
Outlook Therapeutics
Outlook Therapeutics’ primary focus is on its lead clinical program, ONS-5010 which aims to treat wet age related macular degeneration (wet AMD) and other eye diseases specific to the retina. The company aims to launch the candidate as the first approved bevacizumab, which is sold under the trade name of Avastin, in the US, Europe and Japan to treat wet AMD, diabetic macular edema and branch retinal vein occlusion.
That being said, Outlook Therapeutics had no news last week that could relate to its share price. Over the trading period shares of the company were up 31.49 percent to US$2.53 as of 2:46 p.m. EDT on Friday.
Hoth Therapeutics
Hoth Therapeutics is a company working on therapeutics for patients with atopic dermatitis, which is eczema. As such, the company is working on developing its BioLexa platform, a drug compound platform being developed at the University of Cincinnati. The platform has notched positive results in preclinical studies at the University of Miami.
Last week the company announced that it will be presenting at the 9th Annual LD Micro Invitational Conference, which takes place on June 4. Shares of Hoth Therapeutics were up 24.75 percent over the week to US$6.11 as of 2:55 p.m. EDT on Friday.
Aveo Oncology
Aveo Oncology’s primary area of focus is on advancing its portfolio of treatments for unmet medical needs and, of course, oncology. The company’s primary candidate is tivozinab, which it is actively working to commercialize in North America.
The company didn’t have any particularly noteworthy news last week other than its announcement that it will be presenting at the 2019 BIO International Convention on June 5. Shares of Aveo Oncology were up 22.14 percent last week to US$0.76.
Evofem Biosciences
Closing out the list is Evofem Biosciences, which is a company focused on products for women’s health. Its lead product candidate, Amphora, is a multipurpose vaginal pH regulator to regulate vaginal PH within the range of 3.5 to 4.5.
Evofem did not have any news last week that could relate to its share price increase, which rose 20.92 percent to US$6.43 as of 3:33 p.m. EDT on Friday.
Data for the 5 Top NASDAQ Biotech and Pharma Stocks articles is retrieved each Friday at 1:00 p.m. EDT using TradingView’s stock screener. Only companies with a market capitalization greater than $10 million and lower than $500 million prior to the week’s gains are included. Companies within the biotechnology and pharmaceutical sectors are considered.
Don’t forget to follow us at @INN_LifeScience for real-time updates!
Securities Disclosure: I, Jocelyn Aspa, hold no direct investment interest in any company mentioned in this article.